Men and women who took the active drug had severe nextmorning psychomotor and memory impairment some  hours later as well as impairment to driving skills memory and coordination as long as  hours after the drug is taken according to an FDA news release As a result the FDA decided to decrease the recommended starting dose of Eszopiclone as sold by Sunovion under the brand name Lunesta from  mg to  mg  The federal agency noted that health care professionals could increase the dosage as high as  mg while warning of the consequences To help ensure patient safety health care professionals should prescribe and patients should take the lowest dose of a sleep medicine that effectively treats their insomnia said Dr Ellis Unger a drug evaluation director at the FDA Sunovion the company that makes and markets Lunesta did not immediately respond Thursday to CNN requests for comment on the recommended dosage change According to the products website Lunesta is the No  prescribed branded sleep aid with more than  million prescriptions for the drug written The same site states that more than  studies have shown Lunesta to be effective in many different types of insomnia patients adding that there are no restrictions on duration for taking Lunesta